Dr. Mark H. Kirschbaum M.D. Net Worth

Dr. Mark H. Kirschbaum M.D. biography

Dr. Mark H. Kirschbaum M.D. is the Sr. VP & Chief Medical Officer at Cyclacel Pharmaceuticals Inc.

What is the salary of Dr D?

As the Sr. VP & Chief Medical Officer of Cyclacel Pharmaceuticals Inc, the total compensation of Dr D at Cyclacel Pharmaceuticals Inc is $354,730. There are 3 executives at Cyclacel Pharmaceuticals Inc getting paid more, with Spiro George Rombotis having the highest compensation of $772,644.

How old is Dr D?

Dr D is 60, he's been the Sr. VP & Chief Medical Officer of Cyclacel Pharmaceuticals Inc since . There are 3 older and no younger executives at Cyclacel Pharmaceuticals Inc. The oldest executive at Cyclacel Pharmaceuticals Inc is Dr. Robert Westwood Ph.D., 77, who is the Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel..

What's Dr D's mailing address?

Mark's mailing address filed with the SEC is C/O CYCLACEL PHARMACEUTICALS, INC.,, 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ, 07922.

Insiders trading at Cyclacel Pharmaceuticals Inc

Over the last 19 years, insiders at Cyclacel Pharmaceuticals Inc have traded over $6,366,241 worth of Cyclacel Pharmaceuticals Inc stock and bought 3,400,245 units worth $14,147,428 . The most active insiders traders include Capital Ltd Portfolio Servi..., Austin W & Greenhouse David... oraz Kevin Ctang Capital Managem.... On average, Cyclacel Pharmaceuticals Inc executives and independent directors trade stock every 78 days with the average trade being worth of $115,984. The most recent stock trade was executed by Paul Mc Barron on 21 December 2023, trading 1,886 units of CYCC stock currently worth $6,262.

What does Cyclacel Pharmaceuticals Inc do?

cyclacel limited is a pharmaceuticals company located in 46-48 e smithfield, london, united kingdom.

Cyclacel Pharmaceuticals Inc executives and stock owners

Cyclacel Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Spiro George Rombotis,
  Pres, CEO & Exec. Director
• Dr. Judy H. Chiao,
  VP of Clinical Devel. & Regulatory Affairs
• Paul McBarron,
  Exec. VP, CFO, COO, Sec. & Exec. Director
• Dr. Mark H. Kirschbaum M.D.,
  Sr. VP & Chief Medical Officer
• Dr. Robert Westwood Ph.D.,
  Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel.
• Gill Christie,
  Director of HR
• Gregory T. Hradsky,
  Director
• Kevin Ctang Capital Managem...,
  
• Judy Chiao,
  V.P., Clin. Dev. & Reg. Aff.
• Nicholas G Bacopoulos,
  Director
• Christopher S Henney,
  Director
• David C Uprichard,
  Director
• Lloyd Sems,
  Director
• Sam L Barker,
  Director
• John Michael Middlecott Banham,
  Director
• Spiro George Rombotis,
  President and CEO
• Capital Ltd Portfolio Servi...,
  
• Robert J. Spiegel,
  Director
• Brian Schwartz,
  Interim Chief Medical Officer
• Daniel K Spiegelman,
  Director
• Austin W & Greenhouse David...,
  10% owner
• Stanley Morgan,
  10% owner
• Robert Edward Sosnowski,
  VP, Marketing & Sales
• James Edeerfield Capital Lp...,
  
• Willian Collins,
  General Manager
• Gregory Reyes,
  Senior VP, Research
• Pierre Legault,
  Director
• John Gordon Mc Vie,
  Director
• Robert Westwood,
  V.P., Chem. & Preclin. Dev.
• Jean Deleage,
  
• Robert Jackson,
  S.V.P. & Chief Scientific Offi
• Mark Kirschbaum,
  Chief Medical Officer
• Paul Mc Barron,
  See Remarks
• Karin L Walker,
  Director
• Kenneth M. Ferguson,
  Director